Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

hVIVO readies flu vaccine for final stage trial as it sails through phase II

“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
syringe
FLU-v is a single injection

A ‘universal’ flu vaccine moved a step nearer as hVIVO PLC (LON:HVO) reported good responses in a phase IIb trial of its new treatment FLU-v.

Trevor Phillips, hVIVO’s executive chairman, said FLU-v is now positioned to enter a Phase III trial, with clear disease and symptom-based endpoints identified. 

WATCH: hVIVO PLC gearing up for Phase III trial of its flu vaccine FLU-v

The trial hit both its primary and secondary endpoints with a reduction in influenza infection rates and severity and duration of symptoms also observed.

FLU-v product profile is a broad spectrum (A, B and Pandemic strains), stand-alone, single injection influenza vaccine.

Phillips added FLU-v can potentially address a much larger patient population than current flu vaccines and has blockbuster sales potential. 

FLU-v is being developed by Imutex Limited, hVIVO's 49% joint venture with the SEEK Group. 

Gregory Stoloff, SEEK’s chief executive, said: "The disease and symptom reduction seen with this "universal" influenza vaccine candidate is achieved by stimulating an immune response mediated through T&B-cells to internal conserved influenza proteins in contrast to seasonal influenza vaccines that prevent infection through antibody protection against external variable proteins. 

“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain."

In this (EU-funded) trial 176 subjects (aged 18-60 years) were assigned to either placebo or treatment arms.

The primary endpoint was to assess the immunogenicity responses of different formulations and regimens versus placebo at 42 and 180 days post-vaccination in healthy volunteers.

Shares jumped 25% to 25p.

View full HVO profile View Profile

hVIVO PLC Timeline

Newswire
September 02 2016

Related Articles

DNA sequence
Thu
The cell therapy specialist also reported there had been industry interest around its main programmes
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use